Testosterone treatment: who will benefit the most?

Lancet Healthy Longev. 2023 Oct;4(10):e524-e525. doi: 10.1016/S2666-7568(23)00191-5.

Authors

Linghui Deng¹, Qiu Shi²

Affiliations

¹ National Clinical Research Center of Geriatrics, Center of Gerontology and Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
² Department of Urology, Institute of Urology and Center of Biomedical Big Data, West China Hospital, Sichuan University, Chengdu 610041, China; Institute of Oncology Research, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. Electronic address: qiushi@scu.edu.cn.

PMID: 37804839
DOI: 10.1016/S2666-7568(23)00191-5

No abstract available

Publication types

Comment

MeSH terms

Androgens / therapeutic use
Humans
Hypogonadism*
Testosterone Congeners
Testosterone* / adverse effects

Substances

Testosterone
Androgens
Testosterone Congeners